Axumin

Chemical Namefluciclovine F 18
Dosage FormInjection (intravenous; 9-221 mCi/mL)
Drug ClassRadioactive diagnostic agents
SystemMale reproductive
CompanyBlue Earth Diagnostics
Approval Year2016

Indication

  • For positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.
Last updated on 12/22/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Axumin (fluciclovine F 18) Prescribing Information 2016Blue Earth Diagnostics Ltd., Oxford, UK
Document TitleYearSource
[18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging—version 1.0.2019European Journal of Nuclear Medicine and Molecular Imaging